PL353854A1 - Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych - Google Patents

Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych

Info

Publication number
PL353854A1
PL353854A1 PL00353854A PL35385400A PL353854A1 PL 353854 A1 PL353854 A1 PL 353854A1 PL 00353854 A PL00353854 A PL 00353854A PL 35385400 A PL35385400 A PL 35385400A PL 353854 A1 PL353854 A1 PL 353854A1
Authority
PL
Poland
Prior art keywords
dihydropyrrol
pain
derivatives
substituted
treatment
Prior art date
Application number
PL00353854A
Other languages
English (en)
Inventor
MichaelPrzewosny Michael Przewosny
Hans-DietrichStachel Hans-Dietrich Stachel
HermannPoschen-Rieder Hermann Poschen-Rieder
Original Assignee
Grunenthal Gmbhgrunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grunenthal Gmbhgrunenthal Gmbh filed Critical Grunenthal Gmbhgrunenthal Gmbh
Publication of PL353854A1 publication Critical patent/PL353854A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
PL00353854A 1999-08-06 2000-07-25 Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych PL353854A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19936719A DE19936719A1 (de) 1999-08-06 1999-08-06 Substituierte 1,5-Dihydropyrrol-2-on-Derivate
PCT/EP2000/007100 WO2001010833A1 (de) 1999-08-06 2000-07-25 Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen

Publications (1)

Publication Number Publication Date
PL353854A1 true PL353854A1 (pl) 2003-12-01

Family

ID=7917172

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353854A PL353854A1 (pl) 1999-08-06 2000-07-25 Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych

Country Status (25)

Country Link
US (1) US6642267B2 (pl)
EP (1) EP1200402B1 (pl)
JP (1) JP2003506437A (pl)
KR (1) KR20020025214A (pl)
CN (1) CN1378532A (pl)
AR (1) AR028848A1 (pl)
AT (1) ATE304530T1 (pl)
AU (1) AU782435B2 (pl)
BR (1) BR0013311A (pl)
CA (1) CA2381033A1 (pl)
CO (1) CO5200758A1 (pl)
CZ (1) CZ2002441A3 (pl)
DE (2) DE19936719A1 (pl)
ES (1) ES2248104T3 (pl)
HK (1) HK1046405A1 (pl)
HU (1) HUP0201937A3 (pl)
IL (1) IL147977A0 (pl)
MX (1) MXPA02001212A (pl)
NO (1) NO20020574L (pl)
NZ (1) NZ516988A (pl)
PE (1) PE20010402A1 (pl)
PL (1) PL353854A1 (pl)
SK (1) SK1702002A3 (pl)
WO (1) WO2001010833A1 (pl)
ZA (1) ZA200201788B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
NZ566062A (en) * 2005-09-28 2009-08-28 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders comprising an arylcycloalkylamine such as ketamine and a biocompatible polymer
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2324126B1 (en) 2008-08-12 2014-04-23 Zinfandel Pharmaceuticals, Inc. METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
MA34828B1 (fr) 2011-01-10 2014-01-02 Zinfandel Pharmaceuticals Inc Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) * 2016-12-06 2020-07-07 Intelligrated Headquarters, Llc Phased deployment of scalable real time web applications for material handling system
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL258360A (pl) * 1960-11-25
GB2173499A (en) * 1985-02-04 1986-10-15 Ici Plc Fungicidal dithiolopyrrolones
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
IL147977A0 (en) 2002-09-12
HUP0201937A2 (en) 2002-10-28
WO2001010833A1 (de) 2001-02-15
CA2381033A1 (en) 2001-02-15
ATE304530T1 (de) 2005-09-15
NO20020574D0 (no) 2002-02-05
EP1200402B1 (de) 2005-09-14
HUP0201937A3 (en) 2002-12-28
ES2248104T3 (es) 2006-03-16
CO5200758A1 (es) 2002-09-27
DE50011178D1 (de) 2005-10-20
EP1200402A1 (de) 2002-05-02
CZ2002441A3 (cs) 2002-05-15
JP2003506437A (ja) 2003-02-18
PE20010402A1 (es) 2001-05-05
NO20020574L (no) 2002-03-25
AU782435B2 (en) 2005-07-28
US20020161033A1 (en) 2002-10-31
BR0013311A (pt) 2003-01-28
DE19936719A1 (de) 2001-02-15
ZA200201788B (en) 2003-08-27
KR20020025214A (ko) 2002-04-03
NZ516988A (en) 2004-11-26
SK1702002A3 (en) 2002-07-02
US6642267B2 (en) 2003-11-04
CN1378532A (zh) 2002-11-06
MXPA02001212A (es) 2002-07-02
AU6827900A (en) 2001-03-05
HK1046405A1 (zh) 2003-01-10
AR028848A1 (es) 2003-05-28

Similar Documents

Publication Publication Date Title
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0105079A3 (en) Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
GB9911053D0 (en) 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
HK1047580A1 (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes.
PL363907A1 (pl) Skondensowane pochodne pirydyny do zastosowania jako antagoniści receptora waniloidowego do leczenia bólu
AP2004003007A0 (en) 3-Azabicyclo (3.1.0) hexane derivatives as oploid receptor antagonists.
PL356990A1 (pl) Pochodne izoksazolokarboksyamidu
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
ZA200110254B (en) Process for the preparation of herbicidal derivatives.
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
AU5497000A (en) Non-malignant disease treatment with ras antagonists
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
IL147978A0 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
HUP9902737A3 (en) The use of aryl-cyclohexylamine derivatives for preparing pharmaceutical compositions suitable for treatment of cns disorders
HK1049151A1 (zh) 四氫化苯並吲衍生物、其製備方法和用作5-ht7受體拮抗劑的用途
HUP0000982A2 (en) Process for the preparation of 1,1-dioxo-penicillanic acid derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)